Tempest Therapeutics, Inc.

NASDAQ (USD): Tempest Therapeutics, Inc. (TPST)

Last Price

0.895

Today's Change

+0.002 (0.22%)

Day's Change

0.88 - 0.905

Trading Volume

479,020

Overview

Market Cap

39 Million

Shares Outstanding

43 Million

Avg Volume

2,381,465

Avg Price (50 Days)

0.90

Avg Price (200 Days)

1.91

PE Ratio

-0.59

EPS

-1.53

Earnings Announcement

17-Mar-2025

Previous Close

0.89

Open

0.89

Day's Range

0.8801 - 0.905

Year Range

0.699 - 6.0

Trading Volume

479,020

Price Change Highlight

1 Day Change

0.26%

5 Day Change

-8.65%

1 Month Change

11.90%

3 Month Change

-19.35%

6 Month Change

-59.68%

Ytd Change

4.29%

1 Year Change

-78.94%

3 Year Change

-74.92%

5 Year Change

-99.27%

10 Year Change

-99.99%

Max Change

-99.95%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment